7:00 am Check-In & Breakfast
8:25 am Chair’s Opening Remarks
Innovations Within Bispecific Antibodies for Unlocking Success Within Solid Tumors
8:30 am Progressing Co-Stimulatory Bispecific Antibodies for Streamlined Translation into the Clinic & Beyond
Synopsis
- Delving into Regeneron’s advancing co-stimulatory bispecific pipeline
- Combinations of co-stimulatory bispecifics to better mimic natural T cell responses
- Next-gen costimulatory molecules and case studies
9:00 am Zenocutuzumab, a HER2xHER3 Biclonics® Antibody That Can Overcome HER3 Mediated NRG1 Signaling In Tumor Cells By Docking On HER2
Synopsis
- Uncovering Merus’ bispecific antibody screening platform to identify novel Biclonics and Triclonics antibodies
- Detection of NRG1 fusions & therapeutic targeting of NRG1 fusion positive patients, a biomarker-driven rare entity (with a significant unmet medical need)
- Zenocutuzumab shows Robust and Durable Responses in NRG1+ Cancer
9:30 am ImmTACs, a Novel Class of Soluble Bispecifics: What Have We Learned So Far?
Synopsis
- Overview of the technology & challenges associated with the platform
- Clinical proof of concept
- Development of a new ImmTac against PIWIL-1, a novel colorectal cancer target
10:00 am High-Throughput Discovery of Functional Bispecific Antibodies From Mammalian Libraries
Synopsis
- OmniAb’s xPloration® single cell screening platform and OmniClic® common light chain human IgG transgenic chickens enable and accelerate discovery of bispecific libraries in the classic IgG-like format
- Demonstrate high-throughput discovery of functional asymmetric bispecific antibody clones from a mammalian secretion library
- Greatly surpass the reformatting/screening matrix bottleneck by enabling screening of millions of designs
10:30 am Morning Break
Reinventing Bispecific Drugs for Autoimmune & Inflammatory Diseases
11:00 am Revolutionizing Bispecific Drugs for Autoimmune & Inflammatory Diseases Treatment of Autoantibody-Driven Diseases with Bispecific T Cell Engaging IgM Antibodies
Synopsis
- Highlighting the unique potential of IgM antibodies for treatment of autoimmune disease
- Utilizing T cells to drive deep B cell depletion for B cell mediated autoimmune diseases
- Sharing pipeline updates including the ongoing imvotamab (CD20 x CD3) Phase 1b clinical trials
12:00 pm Reinventing Autoimmune Disease & Cancer Treatment by Harnessing NK Cells
Synopsis
- Validated Flex-NK™ bispecific antibody scaffold for developing next generation of NK cell redirected antibody therapeutics for Autoimmune disease and Cancer
- CD38 a well differentiated target for B cell mediated autoimmune diseases and the unique mechanism of action of CYT-338 NK cell engaged
- Cytovia 2.0 emerging pipeline based on NK cell therapy’s for the treatment of autoimmune and cancer indications
12:30 pm Immuno-STATs: a Novel Class of T Cell Engagers for B Cell Depletion in Autoimmune Diseases
Synopsis
- Immuno-STATs are a new class of TCR-selective engagers for selective modulation of disease-relevant T cells
- CUE-100 series Immuno-STATs have been clinically validated in oncology, and have demonstrated significant increase in efficacy (ORR and mPFS) vs SoC
- Here we describe the CUE-500 series, which can re-direct the protective virus-specific T cells (VSTs) to deplete B cells, hence providing unprecedented selectivity for exploiting the killing potential of VSTs, and positions this class of biologics as an attractive alternative for CAR-T approaches
1:00 pm Lunch
Going Beyond The Backbone of T Cell Engagers – A New Generation of Immune Cell Engagers
2:00 pm Considerations on T vs NK Cell Engagers & Case Studies
Synopsis
- Exploring a next generation of NK cell engagers acting via two activating receptors
- Discussing differences between next generations of NK and T cell engages
2:30 pm Advancing T-cell Engagers for Solid Tumors
Synopsis
- T cell engager molecules have demonstrated clinical benefit in hematological malignancies and there is growing evidence of activity in solid tumors
- This presentation will highlight key findings from recent trials along with observations from nonclinical studies that inform on T cell engager molecule mechanism of action and new engineering approaches to address clinically-observed challenges
3:00 pm A Next Generation T Cell Engager Leveraging a Novel Format
3:30 pm Afternoon Break
Going Beyond The Backbone of T Cell Engagers – A New Generation of Immune Cell Engagers
4:00 pm Selectively Activating Subsets of T Cells Present in Tumor-Infiltrating Lymphocytes of Solid Tumors to Promote More Potent Anti-Tumor Activity
Synopsis
- Uncovering associations between Vβ T cell subsets and diseases, including specific cancers, autoimmune and infectious diseases
- Outlining the strategy of stimulating only a defined subset of αβ T cells
- Exploring Marengo’s pipeline of novel TCEs for both hot and cold tumors
4:30 pm Moving Beyond Bispecifics with Multivalent T cell Engagers in Solid Tumors
Synopsis
- ModeX’s multispecific antibody platform technology designed for syngergistic targeting and streamlined manufacturing in a single product
- The pathway from design, creation, and characterization to the clinic
- Utilizing information about validated targets and known immune mechanisms to characterize clinical safety and efficacy in patients with advanced solid tumors